Calib-og, Merlyn G.
HRN: 24-05-06 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/27/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
01/27/2025
02/10/2025
IV
1.5
Q8
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes